🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Australia / NCT07532603
Recruiting Phase 2/3

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

NCT07532603 · tracked via the Priya Life Science Australia tracker
Phase
Phase 2/3
Started
2026-03-19
Last updated
2026-07-08

Condition(s) studied

Lichen Planopilaris

Investigational drug(s) / intervention(s)

Oral Brepocitinib →Placebo

Oral Brepocitinib: Oral

Placebo: Oral

Study summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years 2. Scalp biopsy consistent with LPP 3. Active and symptomatic LPP at screening and baseline- 4. Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2 Exclusion Criteria: 1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer). 2. High risk of thrombosis or cardiovascular disease 3. High risk of herpes zoster 4. Active or recent infection

Primary outcome measure(s)

Trial sites (61)

FacilityCityRegionStatus
Clinical Trial Site Birmingham Alabama Recruiting
Clinical Trial Site Phoenix Arizona Recruiting
Clinical Trial Site Scottsdale Arizona Recruiting
Clinical Trial Site Irvine California Recruiting
Clinical Trial Site Oakland California Recruiting
Clinical Trial Site Sacramento California Recruiting
Clinical Trial Site San Francisco California Recruiting
Clinical Trial Site Denver Colorado Recruiting
Clinical Trial Site Farmington Connecticut Recruiting
Clinical Trial Site New Haven Connecticut Recruiting
Clinical Trial Site Miami Florida Recruiting
Clinical Trial Site Chicago Illinois Recruiting
Clinical Trial Site Skokie Illinois Recruiting
Clinical Trial Site Clarksville Indiana Recruiting
Clinical Trial Site Indianapolis Indiana Recruiting
Clinical Trial Site Leawood Kansas Recruiting
Clinical Trial Site Louisville Kentucky Recruiting
Clinical Trial Site Boston Massachusetts Recruiting
Clinical Trial Site Burlington Massachusetts Recruiting
Clinical Trial Site Ann Arbor Michigan Recruiting
Clinical Trial Site Ann Arbor Michigan Recruiting
Clinical Trial Site Medina Minnesota Recruiting
Clinical Trial Site Minneapolis Minnesota Recruiting
Clinical Trial Site Kansas City Missouri Recruiting
Clinical Trial Site Lee's Summit Missouri Recruiting
Clinical Trial Site Lebanon New Hampshire Recruiting
Clinical Trial Site New Hyde Park New York Recruiting
Clinical Trial Site New York New York Recruiting
Clinical Trial Site Durham North Carolina Recruiting
Clinical Trial Site Cleveland Ohio Recruiting
Clinical Trial Site Columbus Ohio Recruiting
Clinical Trial Site Medina Ohio Recruiting
Clinical Trial Site Portland Oregon Recruiting
Clinical Trial Site Philadelphia Pennsylvania Recruiting
Clinical Trial Site Charleston South Carolina Recruiting
Clinical Trial Site Murfreesboro Tennessee Recruiting
Clinical Trial Site Smyrna Tennessee Recruiting
Clinical Trial Site Austin Texas Recruiting
Clinical Trial Site Austin Texas Recruiting
Clinical Trial Site Cedar Park Texas Recruiting

+ 21 more sites — see the full list on the official registry below.

More Priovant Therapeutics, Inc. trials in Australia

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07532603 on ClinicalTrials.gov ↗ ← All trials in Australia